<DOC>
	<DOC>NCT01925274</DOC>
	<brief_summary>This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of cetuximab plus Irinotecan. A Japanese Lead in Cohort will assess the safety of the combination of PF-05212384 + irinotecan in patients enrolled at Japanese sites.</brief_summary>
	<brief_title>A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>KRAS and NRAS wild type metastatic colorectal cancer Progression following treatment for colorectal cancer with irinotecan, oxaliplatin and fluoropyrimidine therapy in the metastatic setting. Eastern Cooperative Oncology Group [ECOG] Performance Status of 0, 1, or 2 At least one measurable lesion by Response Evaluation Criterion in Solid Tumors [RECIST] More than 2 prior cytotoxic chemotherapy regimens for metastatic colorectal cancer. Prior treatment with a PI3K, mTOR, AKT or EGFR inhibitor Patients who have discontinued treatment with prior irinotecan therapy due to toxicity. Prior radiation to the pelvis or abdomen Patients with history of interstitial lung disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>KRAS</keyword>
	<keyword>colon cancer</keyword>
	<keyword>mCRC</keyword>
	<keyword>CRC</keyword>
	<keyword>PF-05212384</keyword>
	<keyword>KRAS wild type colorectal cancer</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cetuximab</keyword>
	<keyword>NRAS</keyword>
</DOC>